# Intravenous Mepolizumab In Children With Eosinophilic Esophagitis

> **NCT00358449** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 84 (actual)

## Conditions studied

- Oesophagitis, Eosinophilic

## Interventions

- **DRUG:** mepolizumab

## Key facts

- **NCT ID:** NCT00358449
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09-11
- **Primary completion:** 2008-11-25
- **Final completion:** 2008-11-25
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2018-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00358449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00358449, "Intravenous Mepolizumab In Children With Eosinophilic Esophagitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00358449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*